| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.3 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.048 | 0.3 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.3 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.04 | 0.3 |